Edition:
United Kingdom

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

533.05INR
18 May 2018
Change (% chg)

Rs-20.70 (-3.74%)
Prev Close
Rs553.75
Open
Rs555.00
Day's High
Rs556.00
Day's Low
Rs530.00
Volume
1,708,157
Avg. Vol
1,807,137
52-wk High
Rs663.40
52-wk Low
Rs480.20

Chart for

About

Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered... (more)

Overall

Beta: 0.47
Market Cap(Mil.): Rs471,067.19
Shares Outstanding(Mil.): 804.69
Dividend: 2.00
Yield (%): 0.34

Financials

  CIPL.NS Industry Sector
P/E (TTM): 43.76 30.95 32.75
EPS (TTM): 13.38 -- --
ROI: -- 14.84 14.38
ROE: -- 16.34 16.07

Indian shares fall as oil companies slip; Vedanta hits over 10-month low

May 23 Indian shares fell on Wednesday pulled down by oil companies, while mining and energy conglomerate Vedanta Ltd hit an over 10-month low as protests against its copper plant in south India turned violent.

8:13am BST

UPDATE 1-India's Cipla posts Q4 profit, misses estimates

May 22 Cipla Ltd, India's second-biggest drugmaker by market capitalization, posted a fourth-quarter profit on Tuesday, but missed street estimates.

22 May 2018

India's Cipla posts Q4 profit

May 22 Cipla Ltd, India's second-biggest drugmaker by market capitalization, posted a fourth-quarter profit on Tuesday, but missed analysts' estimates.

22 May 2018

BRIEF-Cipla Partners With Mannkind For Marketing, Distribution Of Afrezza In India

* PARTNERS WITH MANNKIND FOR EXCLUSIVE MARKETING, DISTRIBUTION OF AFREZZA IN INDIA

09 May 2018

BRIEF-Mannkind And Cipla Enter An Exclusive Marketing And Distribution Agreement For Afrezza® In India

* MANNKIND AND CIPLA ENTER AN EXCLUSIVE MARKETING AND DISTRIBUTION AGREEMENT FOR AFREZZA® IN INDIA

09 May 2018

BRIEF-India's Cipla Gets Final Nod For Generic Vazculep, Others

* GETS FINAL NOD FOR GENERIC VAZCULEP, GENERIC PHENYLEPHRINE HYDROCHLORIDE INJECTION USP, 10 MG/ML SINGLE-DOSE VIAL, GENERIC AROMASIN

02 May 2018

BRIEF-Cipla's JV Saba Investment Completes Disinvestment Of Stake Held In Al Jabal For Drugs And Medical Appliances

* CO'S JV SABA INVESTMENT COMPLETED DISINVESTMENT OF 99 PERCENT STAKE HELD IN AL JABAL FOR DRUGS AND MEDICAL APPLIANCES CO Source text: http://bit.ly/2GsCYiw Further company coverage:

26 Mar 2018

BRIEF-India's Cipla Says Unit Launches Authorized Generic Version Of Aloxi In U.S.

* SAYS ‍CO'S UNIT LAUNCHES AUTHORIZED GENERIC VERSION OF ALOXI IN U.S. Source text - http://bit.ly/2pEclNR Further company coverage:

26 Mar 2018

BRIEF-Medrx says drug development and sale contract change

* Says it enters into a license contract with Cipla Ltd's wholly owned unit Cipla Technologies, LLC, instead of with Cipla Ltd's wholly owned unit Cipla USA Inc preciously, on development and sale of MRX-4TZT, transdermal patch for the treatment of spastic paralysis, due to Cipla group' s reorganization

23 Mar 2018

BRIEF-Cipla's Goa Unit FDA Inspection Finds Lab Records Deficient - TV

* CIPLA LTD GOA UNIT'S U.S. FDA INSPECTION FINDS THAT LAB RECORDS DEFICIENT, RECORDS DON'T INCLUDE COMPLETE TESTING DATA - TV Source text - http://bit.ly/2u1xLt3 Further company coverage:

20 Mar 2018

Earnings vs. Estimates